Trial Profile

XanaHES: a Phase I, Single Blinded, Central Reader Blinded, Placebo-Controlled, Dose Escalation Study of Xanamem™ to Assess Safety and Tolerability in Healthy Elderly Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emestedastat (Primary)
Indications Alzheimer's disease
Focus Adverse reactions
Acronyms XanaHES
Sponsors Actinogen Medical

Most Recent Events

20 Jul 2023 Results assessing the effects of Xanamem on cognition from XanaHES (n= 42, 20 mg) and XanaMIA (n=105, 5 & 10 mg) and XanADu-X biomarker extension study (n=72, 10 mg), presented at the Alzheimer's Association International Conference 2023.
30 Mar 2023 Results published in the Actinogen Medical Media Release.
28 Jul 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com